Dabrafenib

Overview

Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC 50 s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E , respectively.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Raf | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-14660
• CAS No.: 1195765-45-7
• Molecular Formula: C23H20F3N5O2S2
• Molecular Weight: 519.56
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution
• Availability: In-stock

Source

Original product source